View Item 

Show simple item record

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
dc.contributor.authorLee, Craig R.
dc.contributor.authorLuzum, Jasmine A.
dc.contributor.authorSangkuhl, Katrin
dc.contributor.authorGammal, Roseann S.
dc.contributor.authorSabatine, Marc S.
dc.contributor.authorStein, Charles michael
dc.contributor.authorKisor, David F.
dc.contributor.authorLimdi, Nita A.
dc.contributor.authorLee, Yee Ming
dc.contributor.authorScott, Stuart A.
dc.contributor.authorHulot, Jean-Sébastien
dc.contributor.authorRoden, Dan M.
dc.contributor.authorGaedigk, Andrea
dc.contributor.authorCaudle, Kelly E.
dc.contributor.authorKlein, Teri E.
dc.contributor.authorJohnson, Julie a.
dc.contributor.authorShuldiner, Alan r.
dc.date.accessioned2022-11-09T21:18:18Z
dc.date.available2023-12-09 16:18:17en
dc.date.available2022-11-09T21:18:18Z
dc.date.issued2022-11
dc.identifier.citationLee, Craig R.; Luzum, Jasmine A.; Sangkuhl, Katrin; Gammal, Roseann S.; Sabatine, Marc S.; Stein, Charles michael ; Kisor, David F.; Limdi, Nita A.; Lee, Yee Ming; Scott, Stuart A.; Hulot, Jean-Sébastien ; Roden, Dan M.; Gaedigk, Andrea; Caudle, Kelly E.; Klein, Teri E.; Johnson, Julie a. ; Shuldiner, Alan r. (2022). "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update." Clinical Pharmacology & Therapeutics (5): 959-967.
dc.identifier.issn0009-9236
dc.identifier.issn1532-6535
dc.identifier.urihttps://hdl.handle.net/2027.42/175094
dc.publisherWiley Periodicals, Inc.
dc.titleClinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175094/1/cpt2526_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175094/2/cpt2526.pdf
dc.identifier.doi10.1002/cpt.2526
dc.identifier.sourceClinical Pharmacology & Therapeutics
dc.identifier.citedreferenceMega, J.L. et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119, 2553 – 2560 ( 2009 ).
dc.identifier.citedreferenceScott, S.A. et al. Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. Clin. Pharmacol. Ther. 100, 287 – 294 ( 2016 ).
dc.identifier.citedreferenceKarve, A.M. et al. Contemporary use of ticagrelor in interventional practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am. J. Cardiol. 115, 1502 – 1506 ( 2015 ).
dc.identifier.citedreferenceGandhi, S. et al. Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. Can. J. Cardiol. 30, 1725 – 1731 ( 2014 ).
dc.identifier.citedreferenceDayoub, E.J. et al. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008–2016. JAMA Intern. Med. 178, 943 – 950 ( 2018 ).
dc.identifier.citedreferenceKazui, M. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38, 92 – 99 ( 2010 ).
dc.identifier.citedreferenceShuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849 – 857 ( 2009 ).
dc.identifier.citedreferenceLewis, J.P. et al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J. Thromb. Haemost. 11, 1640 – 1646 ( 2013 ).
dc.identifier.citedreferenceSibbing, D. et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121, 512 – 518 ( 2010 ).
dc.identifier.citedreferenceLee, C.R. et al. Impact of the CYP2C19*17 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention. Clin. Pharmacol. Ther. 109, 705 – 715 ( 2021 ).
dc.identifier.citedreferencePan, Y. et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation 135, 21 – 33 ( 2017 ).
dc.identifier.citedreferenceMega, J.L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821 – 1830 ( 2010 ).
dc.identifier.citedreferenceXi, Z., Fang, F., Wang, J., AlHelal, J., Zhou, Y. & Liu, W. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis. Platelets 30, 229 – 240 ( 2019 ).
dc.identifier.citedreferenceSorich, M.J., Rowland, A., McKinnon, R.A. & Wiese, M.D. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ. Cardiovasc. Genet. 7, 895 – 902 ( 2014 ).
dc.identifier.citedreferenceWiviott, S.D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001 – 2015 ( 2007 ).
dc.identifier.citedreferenceWallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045 – 1057 ( 2009 ).
dc.identifier.citedreferenceWallentin, L. et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376, 1320 – 1328 ( 2010 ).
dc.identifier.citedreferenceGimbel, M. et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet 395, 1374 – 1381 ( 2020 ).
dc.identifier.citedreferenceAmsterdam, E.A. et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130, e344 –e 426 ( 2014 ).
dc.identifier.citedreferenceCollet, J.P. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 42, 1289 – 1367 ( 2021 ).
dc.identifier.citedreferenceLevine, G.N. et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation 124, e574 –e 651 ( 2011 ).
dc.identifier.citedreferenceClaassens, D.M.F. et al. Clopidogrel versus ticagrelor or prasugrel after primary percutaneous coronary intervention according to CYP2C19 genotype: A POPular genetics subanalysis. Circ. Cardiovasc. Interv. 14, e009434 ( 2021 ).
dc.identifier.citedreferenceDayoub, E.J. et al. Use of prasugrel and ticagrelor in stable ischemic heart disease after percutaneous coronary intervention, 2009–2016. Circ. Cardiovasc. Interv. 12, e007434 ( 2019 ).
dc.identifier.citedreferenceWang, Y. et al. Ticagrelor versus Clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N. Engl. J. Med. 385, 2520 - 2530 ( 2021 ).
dc.identifier.citedreferenceMega, J.L. et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306, 2221 – 2228 ( 2011 ).
dc.identifier.citedreferenceHorenstein, R.B. et al. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. J. Clin. Pharmacol. 54, 865 – 873 ( 2014 ).
dc.identifier.citedreferenceCarreras, E.T. et al. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. Thromb. Haemost. 116, 69 – 77 ( 2016 ).
dc.identifier.citedreferenceZhang, L. et al. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis. Thromb. Res. 135, 449 – 458 ( 2015 ).
dc.identifier.citedreferenceAngiolillo, D.J. et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC Cardiovasc. Interv. 13, 606 – 617 ( 2020 ).
dc.identifier.citedreferenceBotton, M.R. et al. Structural variation at the CYP2C locus: characterization of deletion and duplication alleles. Hum. Mutat. 40, e37 – e51 ( 2019 ).
dc.identifier.citedreferencePratt, V.M. et al. Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology. J. Mol. Diagn. 20, 269 – 276 ( 2018 ).
dc.identifier.citedreferenceScott, S.A. et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94, 317 – 323 ( 2013 ).
dc.identifier.citedreferenceCavallari, L.H. et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc. Interv. 11, 181 – 191 ( 2018 ).
dc.identifier.citedreferenceClaassens, D.M.F. et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N. Engl. J. Med. 381, 1621 – 1631 ( 2019 ).
dc.identifier.citedreferencePereira, N.L. et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA 324, 761 – 771 ( 2020 ).
dc.identifier.citedreferencePereira, N.L. et al. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis. JACC Cardiovasc. Interv. 14, 739 – 750 ( 2021 ).
dc.identifier.citedreferenceGalli, M. et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet 397, 1470 – 1483 ( 2021 ).
dc.identifier.citedreferenceBotton, M.R. et al. PharmVar GeneFocus: CYP2C19. Clin. Pharmacol. Ther. 109, 352 – 366 ( 2021 ).
dc.identifier.citedreferenceCPIC. CPIC ® Guideline for Clopidogrel and CYP2C19 < https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/ > ( 2021 ). Accessed March 30, 2021.
dc.identifier.citedreferencePharmGKB. Gene-specific Information Tables for CYP2C19 < https://www.pharmgkb.org/page/cyp2c19RefMaterials > ( 2021 ). Accessed March 30, 2021.
dc.identifier.citedreferenceSibbing, D. et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J. Thromb. Haemost. 8, 1685 – 1693 ( 2010 ).
dc.identifier.citedreferenceVerma, S.S. et al. Genomewide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the international clopidogrel pharmacogenomics consortium. Clin. Pharmacol. Ther. 108, 1067 – 1077 ( 2020 ).
dc.identifier.citedreferenceLewis, J.P. et al. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. Eur. Heart J. Cardiovasc. Pharmacother. 6, 203 – 210 ( 2020 ).
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cpt2526_am.pdf
Size:
362.5KB
Format:
PDF
View/Open
Name:
cpt2526.pdf
Size:
237.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.